<DOC>
	<DOCNO>NCT02094924</DOCNO>
	<brief_summary>This study require confirm suitability candidate FDC 16mg candesartan cilexetil/12.5mg HCTZ ( GSK587323 ) formulation development provide data allow design future pivotal bioequivalence study . This study aim determine relative bioavailability FDC tablet formulation 16mg candesartan cilexetil/12.5mg HCTZ relative reference product fix dose combination ( 16mg candesartan cilexetil/12.5mg HCTZ ) healthy adult human . This open-label , randomise , single dose , two-way crossover study . Each subject participate two treatment period randomize one two sequence administer one two treatment , A B , per randomization schedule . The two treatment period separate washout period 7 14 day ensure candesartan HCTZ effectively eliminate subject dosing occasion . The study enroll 16 healthy subject ensure 14 subject complete study plan .</brief_summary>
	<brief_title>A Relative Bioavailability Study Fixed Dose Combination ( FDC ) Tablets GSK587323</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Subjects Capable give write informed consent , include compliance requirement restriction list consent form Male female age 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator consultation GlaxoSmithKline ( GSK ) Medical Monitor require agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =50kilograms ( kg ) Body Mass Index ( BMI ) within range 19 24.9kg / meter^2 ( m^2 ) ( inclusive ) . A female subject eligible participate : nonchildbearing potential define premenopausal female document tubal ligation hysterectomy definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ; postmenopausal define 12 month spontaneous amenorrhea questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milli international unit per millilitre ( MlU/mL ) estradiol &lt; 40 picograms per millilitre ( pg/mL ) ( &lt; 147 picomol per litre ( pmol/L ) ) confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . A female subject eligible participate childbearing potential negative pregnancy test determine serum urine Human Chorionic Gonadotropin ( hCG ) test screen prior dosing AND agree use one contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception followup contact visit . A female subject eligible participate samesex partner , prefer usual lifestyle . Male subject female partner childbearing potential must agree use one contraception method . This criterion must follow time first dose study medication followup contact visit . Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin 1.5x Upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based single average QT duration correct heart rate ( QTc ) triplicate Electrocardiograms ( ECGs ) obtain brief recording period : QT duration correct heart rate Fridericia 's Formula ( QTcF ) &lt; 450 millisecond ( msec ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram ( g ) alcohol : halfpint ( approximately 240 mL ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Gastrointestinal disease gastrointestinal surgical history affect absorption investigational drug . Any subject systolic blood pressure ( BP ) &lt; 95 millimetre Mercury ( mmHg ) recent history postural symptoms A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . A positive prestudy drug/alcohol screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . Pregnant female determine positive serum urine hCG test screen prior dosing . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Lactating female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Candesartan cilexetil</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Hydrochlorothiazide</keyword>
	<keyword>Healthy adult human subject</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>